June Featured Opportunities
Open Funding Opportunities
Alzheimer's Research Program (AZRP)
Pre-Application Deadline: June 22, 2026
Submission Deadline: September 24, 2026
Amyotrophic Lateral Sclerosis Research Program (ALSRP)
Pre-Application Deadline: June 24, 2026
Submission Deadline: September 30, 2026
Arthritis Research Program (ATRP)
Pre-Application Deadline: July 22, 2026
Submission Deadline: October 22, 2026
Pre-Application Deadline: July 27, 2026
Submission Deadline: October 22, 2026
Breast Cancer Research Program (BCRP)
Pre-Application Deadline: June 12, 2026 (Breakthrough Level 3, Breakthrough Level 4, Transformative Breast Cancer Consortium) & June 24, 2026 (Breakthrough Levels 1 and 2, Clinical Research Extension, Era of Hope Scholar, Transformative Breast Cancer Consortium Development)
Submission Deadline: July 8, 2026 (Breakthrough Levels 1 and 2, Clinical Research Extension, Era of Hope Scholar, Transformative Breast Cancer Consortium Development), September 30, 2026 (Breakthrough Level 3, Breakthrough Level 4, Transformative Breast Cancer Consortium)
Epilepsy Research Program (ERP)
Pre-Application Deadline: August 3, 2026
Submission Deadline: August 17, 2026
Hearing Restoration Research Program (HRRP)
Pre-Application Deadline: August 25, 2026
Submission Deadline: September 10, 2026
Lung Cancer Research Program (LCRP)
Pre-Application Deadline: June 23, 2026 (Idea Development, Translational Research) & August 18, 2026 (Patient-Centered Outcomes and Survivorship)
Submission Deadline: September 2, 2026 (All Opportunities)
Pre-Application Deadline: July 29, 2026
Submission Deadline: August 19, 2026
Melanoma Research Program (MRP)
Pre-Application Deadline: July 13, 2026 (Focused Program – Rare Melanomas, Idea, Team Science) & September 22, 2026 (Melanoma Academy Scholar, Survivorship Research)
Submission Deadline: October 14, 2026 (All Opportunities)
Military Burn Research Program (MBRP)
Pre-Application Deadline: July 7, 2026
Submission Deadline: October 21, 2026
Multiple Sclerosis Research Program (MSRP)
Pre-Application Deadline: July 30, 2026
Submission Deadline: August 13, 2026
Ovarian Cancer Research Program (OCRP)
Pre-Application Deadline: July 13, 2026 (Pilot, Investigator-Initiated Research) & September 15, 2026 (Clinical Trial, Ovarian Cancer Academy – Early-Career Investigator, Ovarian Cancer Academy – Early-Career Investigator)
Submission Deadline: October 1, 2026 (All Opportunities)
Pancreatic Cancer Research Program (PCARP)
Pre-Application Deadline: July 7, 2026 (Idea Development, Translational Research Partnership) & September 16, 2026 (Focused Pilot)
Submission Deadline: October 7, 2026 (All Opportunities)
Peer Reviewed Cancer Research Program (PRCRP)
Pre-Application Deadline: June 26, 2026
Submission Deadline: October 5, 2026
Peer Reviewed Medical Research Program (PRMRP)
Pre-Application Deadline: July 16, 2026 (Discovery, Research Advancement) & July 23, 2026 (Clinical Trial, Platform Clinical Translation, Impact, Lifestyle and Applied Health Research, Technology/Therapeutic Development)
Submission Deadline: July 30, 2026 (Discovery & Research Advancement), August 6, 2026 (Impact, Lifestyle and Applied Health Research, Technology/Therapeutic Development Award) & September 22, 2026 (Clinical Trial, Platform Clinical Translation)
Prostate Cancer Research Program (PCRP)
Pre-Application Deadline: August 12, 2026
Submission Deadline: September 2, 2026
Spinal Cord Injury Research Program (SCIRP)
Pre-Application Deadline: August 3, 2026
Submission Deadline: November 12, 2026
Tick-Borne Disease Research Program (TBDRP)
Pre-Application Deadline: July 22, 2026
Submission Deadline: October 22, 2026
Toxic Exposures Research Program (TERP)
Pre-Application Deadline: August 19, 2026
Submission Deadline: November 19, 2026
Traumatic Brain Injury and Psychological Health Research Program (TBIPHRP)
Pre-Application Deadline: July 13, 2026 (Clinical Trial, Translational Research) & September 24, 2026 (Health Services Research)
Submission Deadline: October 15, 2026
Tuberous Sclerosis Complex Research Program (TSCRP)
Pre-Application Deadline: July 23, 2026
Submission Deadline: August 6, 2026
Pre-Application Deadline: July 28, 2026 (Clinical Trail, Investigator-Initiated Research, Translational Research) & August 25, 2026 (Mentored Clinical Research)
Submission Deadline: November 12, 2026 (Clinical Trail, Investigator-Initiated Research, Translational Research) & September 10, 2026 (Mentored Clinical Research)
NEW Pre-announcements:
Reconstructive Transplant Research Program
Upcoming Lunch and Learn Webinars
June 3: Alzheimer's, Amyotrophic Lateral Sclerosis, Breast Cancer, Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Peer Reviewed Cancer, Peer Reviewed Medical, Vision
June 10: Arthritis, Lupus, Melanoma, Military Burn, Multiple Sclerosis, Traumatic Brain Injury/Psychological Health, Tick Borne Diseases, Tuberous Sclerosis Complex
June 24: Autism, Bone Marrow Failure, Combat Readiness, Epilepsy, Hearing Restoration, Orthopaedic, Reconstructive Transplant, Spinal Cord Injury
July 8: Duchenne Muscular Dystrophy, Joint Warfighter Medical, Kidney Cancer, Neurofibromatosis, Parkinsons, Prostate Cancer, Rare Cancers, Toxic Exposures
Small Business Award Opportunities - Open Topic Areas:
Proposals that address one or more of the following topics are currently being considered:
- Topic 1: Development of an annual test to inform women about their future fertility
- Topic 2: Versatile Bioadhesives
- Topic 3: Universal Platform for Living Adaptive Toxin-removal (UNI-PLAT)
- Topic 4: Breaking Ground: The First Curative, Non-Invasive, Long-Lasting Therapy for Endometriosis
- Topic 5: ARPA-H Lineage Topic
- Topic 6: Rapid Comprehensive Diagnostic Test for Multi-System Autoimmune Disease
- Topic 7: Virtual Human Brain for the Development of Neurosurgical Robotics
Key Dates:
- Solution Summary Due: July 10, 2026 (11:59PM ET)
- Applicants who are successful in the Solution Summary phase will be encouraged to pitch.
- Technical Oral Presentation (Pitch), Cost Proposal, and Task Description Document Due: September 9, 2026 (11:59PM ET)
Reminder: Dates are estimates and subject to change. Please reference the solicitation for the most up-to-date information and proposal instructions.
BoSS – BioStabilization Systems
What ARPA-H needs to solve this problem - BoSS will take inspiration from nature to revolutionize preservation technology. The program has two technical areas: 1) development of cell interventions to enable stabilization and restoration and 2) engineering of scalable cell processing systems that can deploy biostabilization strategies.
Notice ID: ARPA-H-SOL-26-136
ARPA-H invites interested parties to review the solicitation which is posted and maintained on SAM.gov. The solicitation outlines the opportunity and its requirements, key dates and deadlines, submission documents and templates, evaluation criteria for submissions, and information on how to apply.
Key Dates:
- Sidebars: Interested parties have the option to schedule meetings with the Program Manager and team for a 10-minute discussion for clarification about program details. The deadline to register is January 16, 2026. Additional information is forthcoming.
- Solution Summary: A summary is required to submit a proposal.
- Due date for potential performers: February 19, 2026
- Due date for IV & V potential partners: April 17, 2026
- Solution Pitch: Encouraged submissions preferred. Additional details will be provided in a solution summary feedback letter.
- Due date for potential performers: March 26, 2026
- Due date for IV & V potential partners: May 21, 2026
Hearing – Hearing Enchancement through Artificially Intelligent NeurotechnoloGy
What ARPA-H needs to solve this problem - ARPA-H encourages collaborations that integrate expertise across neuroscience, otology, biomedical engineering, microelectronics, machine learning, neuromodulation, clinical audiology, and regulatory science.
Notice ID: ARPA-H-SOL-26-154
ARPA-H invites interested parties to review the solicitation, which is posted and maintained on SAM.gov. The solicitation outlines the opportunity and its requirements, key dates and deadlines, submission documents and templates, evaluation criteria for submissions, and information on how to apply.
Key Dates:
- Solution Summary Due: June 29, 2026 at 2:00PM ET
A summary is required to submit a full proposal. - Full Proposal Due: August 14, 2026 at 2:00PM ET
After submission of a solution summary, proposers will either be encouraged or discouraged from submission of a full proposal. It is strongly recommended that only proposers who are encouraged to submit a full proposal do so.
Reminder: Dates are estimates and subject to change. Please reference the solicitation for the most up-to-date information.
IGoR – Intelligent Generator of Research
What ARPA-H needs to solve this problem - IGoR seeks teams with expertise in computational biology and mechanistic modeling, AI/ML orchestration and agentic systems, laboratory automation and robotics, experimental protocol standardization, distributed systems architecture, and human-centered interface design. Teams should include capabilities spanning disease biology, data engineering, and validated wet-lab experimentation across multiple modalities. Teams may include academic institutions, non-profit organizations, companies, or a combination of highly skilled performers across sectors. The program has four technical areas for which performers must develop: 1) mechanistic disease models that encode causal biological relationships across scales, 2) an AI orchestration layer that identifies knowledge gaps and designs optimal experiments, 3) a layered protocol architecture that enables any qualified laboratory to execute the same experiment reproducibly, and 4) a distributed marketplace of validated laboratories that execute standardized protocols and return gold-standard data.
Notice ID: ARPA-H-SOL-26-155
ARPA-H invites interested parties to review the solicitation, which is posted and maintained on SAM.gov. The solicitation outlines the opportunity and its requirements, key dates and deadlines, submission documents and templates, evaluation criteria for submissions, and information on how to apply.
Key Dates:
- Solution Summary Due: June 25, 2026, 12:00PM ET
A summary is required to submit a full proposal. - Full Proposal Due: August 6, 2026, 12:00PM ET
After submission of a solution summary, proposers will either be encouraged or discouraged from submission of a full proposal. It is strongly recommended that only proposers who are encouraged to submit a full proposal do so.
Reminder: Dates are estimates and subject to change. Please reference the solicitation for the most up-to-date information.
Pre-Announcement: “PRimer and prObe Manufacturing PlaTform (PROMPT)”
Technology development and progress are urgently needed to address critical capability gaps in expeditionary medical diagnostics. Current diagnostic capabilities are hindered by a reliance on centralized manufacturing for essential nucleic acid amplification test (NAAT) reagents, such as primers and probes. This paradigm is currently incompatible with the demands of agile, far-forward medical responses to novel biothreats. An effective prototype must overcome several key challenges identified across the current landscape. Technologically, it must replace the current hazardous and environmentally sensitive synthesis systems with field-stable chemistry and ruggedized hardware. Any proposed system must integrate a deployable, effective method for both the purification of synthesized reagents and their subsequent quality control and validation, as this represents a major unsolved problem. Finally, any successful prototype must be developed with a clear strategy to navigate the currently undefined regulatory pathway for far-forward manufactured diagnostics.
Pre-Announcement: “Autonomous Closed Loop Control Mechanical Ventilation (ACLCMV)”
This effort focuses on the development of an autonomous closed loop control (ACLC) mechanical ventilator (MV). This device is expected to use advanced algorithms to automatically adjust ventilation settings for closed loop Positive End Expiratory Pressure (PEEP) based on the patient's physiological responses, minimizing the need for manual intervention. The goal is to create a lightweight, durable, and power-efficient ventilator that enhances patient safety and frees up medical personnel for other critical tasks during aeromedical evacuation and prolonged field care scenarios.
Pre-Announcement: "Multi-Topic Request for Proposals: Military Medical Prototype Advancement”
(BRAIN CONNECTS): Specialized Projects for Scalable Technologies (U01 Clinical Trial Not Allowed)
NIH Small Business Technology Transfer Grant (Parent STTR [R41/R42] Clinical Trial Optional)
SBIR/STTR Commercialization Readiness Pilot (CRP) Program (Parent SB1 Clinical Trial Optional)
Influenza Modeling and Forecasting
- Specific Area of Interest: This RFP seeks to support independent medical education initiatives that address unmet educational needs in recognition of RSV as a risk for cardiorespiratory events, understand emerging data on RSV vaccination and cardiorespiratory outcomes, and current RSV guidelines in adults.
Educational projects should improve HCP understanding and knowledge of:
The epidemiology, burden, and outcomes of RSV infection in adults, particularly those with cardiovascular disease
The relationship between RSV and cardiovascular morbidity and mortality
Emerging real world evidence evaluating RSV prevention impact on cardiorespiratory outcomes
Current recommendations for adult RSV vaccination
The role of cardiology professionals in identifying, counseling, and managing patients eligible for adult immunization
The importance of RSV prevention as a part of management of patient’s cardiovascular disease and practical considerations for integrating immunization discussions into practice
Examples of Educational Formats: Considered Projects may include one or more of the following, but are not limited to:
Agenda educational session at a live cardiology conference
Independent CME symposia or educational series alongside major cardiology congresses, such as: American College of Cardiology (ACC), American Heart Association (AHA), other key national cardiology meetings
Peer-to-peer education
Online articles, newsletter articles, training courses, webinars
Videos, podcasts, infographics, animations Peer-to-peer educational forums
Enduring materials linked to congress-based education (e.g., recordings, toolkits, digital resources)
Pfizer - Implementing Shared Decision Making in Hemophilia Patient Care – Due July 21, 2026
Specific Area of Interest:
- Implementing shared decision making (SDM) tools and/or management of care algorithms into hemophilia patient care. Multi-disciplinary collaborations are encouraged when appropriate, but all partners must have a relevant role.
- Identifying significant barriers that contribute to geographic, gender and racial healthcare disparities disproportionately impacting the Hemophilia Community. The goal is to enhance early detection and determine targeted interventions that address these challenges with focus on SDM.
- Exploring empowering strategies that enable patients to actively participate in their care, as well as in making informed decisions regarding disease management options.
- Implementing and evaluating patient-reported outcome (PRO) tools in hemophilia care to capture the patient voice, improve understanding of treatment burden and quality of life, and support shared decision making (SDM).
Specific Area of Interest: This competitive grant seeks to encourage organizations to submit grant applications for education activities designed to increase healthcare professional understanding and awareness of most recent clinical data and practical therapy management strategies for patients with ALK-positive Metastatic Non-Small Cell Lung Cancer (mNSCLC) with a particular focus on community oncology practice.
Specific Area of Interest: Projects that will be considered for Pfizer support will focus on basic science and fundamental biological understanding of Tissue Factor Pathway Inhibitor (TFPI), anti-TFPI Monoclonal Antibodies, and marstacimab. The areas of interest may include (but are not limited to):
- Basic biology of TFPI including interactions among key regulatory proteins in the intrinsic and/or extrinsic clotting cascades (e.g. Protein S being a co-factor for both Protein C and TFPI).
- Impact of differential TFPI expression within tissues and the role of various TFPI pools/isoforms in the regulation of coagulation.
- Pharmacology resulting from concomitant therapies added to anti-TFPI.
Specific Area of Interest: Potential applicants are encouraged to identify and address preclinical/basic science data generation for TFPI modulation/rebalancing in their local setting. This may include:
- Rare bleeding disorders which arise from deficiencies in different clotting factors or pathway components but converge on a common functional endpoint which is an impaired thrombin generation (e.g., Factor II, Factor V, Factor VII, Factor X and Factor XI deficiencies, as well as von Willebrand disease).
- Other diseases such as Glanzmann's thrombasthenia (GT) that have a distinct pathophysiological mechanism.
- Other rare bleeding disorders whose mechanisms are not well understood (e.g., Bleeding Disorder of Unknown Cause, BDUC).
Please note proposals related to hemophilia A (FVIII deficiencies) and hemophilia B (FIX deficiencies) are out of scope for this RFP.
Specific Area of Interest: The overall aim of this RFP is to develop innovative, impactful, scalable, and sustainable quality improvement projects to advance the delivery of quality care to patients with mPCa. Funded projects should aim to address knowledge gaps, inefficiencies, and disparities in care delivery by focusing on one or more of the following areas:
- Optimizing provider adherence to standard of care testing and treatment strategies, ensuring access to up-to-date, evidence-based care.
- Enhancing patient–provider communication and health literacy, thereby improving patient understanding of disease, treatment options, and care pathways to optimize clinical outcomes.
- Improving strategies for toxicity mitigation, with the goal of increasing treatment tolerability and enabling patients to receive and remain on life-prolonging therapies.
- Increasing appropriate utilization of biomarker and genetic testing, to support access to targeted therapies for eligible patients.
Bureau of Global Health Security and Diplomacy - Advancing Global Health - DFOP0017890
Closing Date: February 14, 2027
The Department of State invites eligible applicants to advance the America First Global Health Strategy, which aims to save lives, strengthen health systems, enhance efficiency, foster self-reliance, and ensure U.S. investments benefit American safety, strength, and prosperity. This Annual Program Statement (APS) establishes a supplemental framework through which the Department of State may identify and support projects that complement, extend, and/or fill identified gaps in the implementation of these bilateral MOUs. Through specific Addenda, the Department will signal priorities and needs.